N/A
N=154
SMS HPV Vaccine Reminders
Human Papillomavirus Vaccination
Bottom Line
View on ClinicalTrials.gov: NCT05151367 ↗Enrolled (actual)
154
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Number of Participants Who Received the Next HPV Vaccine Dose — 51; 27 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Text message reminder (Behavioral)
- Age
- Pediatric · 10+ yrs
- Sex
- Female
- Sponsor
- Columbia University
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Received the Next HPV Vaccine Dose |
51; 27 | — |
Summary
This study will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic, also in Kampala. While text messages can be used in populations with low literacy, families can opt to receive automated phone call reminders instead. The investigators will pilot assess the impact of vaccine reminders on human papillomavirus (HPV) vaccination. Caregivers of preteens/adolescents will be randomized and stratified by site, language and HPV vaccine dose needed (initiation vs. completion). As this is a feasibility trial, the investigators expect to measure effect size but not necessarily achieve statistical significance.
Eligibility Criteria
Inclusion Criteria
- Be a parenting adult of an adolescent girl aged 10-14 years
- Reside in Kampala and/or the surrounding districts
- Speak English or Luganda
- Have a cell phone with text messaging capability
- Must have ability to consent
Exclusion Criteria
- Parenting adult speaks other language than English or Luganda only
- Parenting adult already enrolled in the study for another child
- Participation in pretesting activities
Data sourced from ClinicalTrials.gov (NCT05151367). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.